June 2016 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Find a Funding Opportunity.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development

For the published request for proposals, see the November 14, 2016 solicitation, Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development.

Nonhuman Primate Virology Laboratory for AIDS Vaccine Research and Development

For the published request for proposals, see the November 17, 2016 solicitation, Nonhuman Primate Virology Laboratory for AIDS Vaccine Research and Development.

Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccine Research and Development

For the published request for proposals, see the February 22, 2017 solicitation, Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccine Research and Development.

Reagent Resource Support Program for AIDS Vaccine Development

For the published request for proposals, see the November 29, 2016 solicitation, Reagent Resource Support Program for AIDS Vaccine Development.

Innovation for HIV Vaccine Discovery

Request for Applications—proposed FY 2018 initiative

Contact: Jon Warren

Objective: The objective of this initiative is to stimulate research on novel, high-risk/high-impact, early discovery vaccine concepts and targets that may have significant impact on the design and development of immunogens or immunization strategies for an effective HIV vaccine.

Description: As in the prior Innovation for HIV Vaccine Discovery initiatives, this renewal initiative will support basic vaccine discovery research that may lead to identifying new target molecules or approaches that help design an effective HIV vaccine. Examples of responsive research include but are not limited to:

  • Novel approaches to elicit durable cellular responses and/or broadly neutralizing protective antibodies against HIV and/or SIV
  • Novel approaches to direct protective adaptive and/or innate immune responses to relevant mucosal or systemic sites
  • Exploring the utility of synthetic vectors for immunogen delivery
  • Developing new animal models, vectors, assays, and adjuvant and/or vaccine formulations if specifically linked to a novel vaccine intervention strategy for preventing acquisition or clearance of virus-infected cells; evaluating proposed hypotheses with appropriate animal models is encouraged (e.g., with nonhuman primate or humanized mice models)
  • Using clinical specimens to answer questions about systemic and/or mucosal immune responses to HIV infection in humans that could lead to vaccine improvements
  • The potential of host or non-host (e.g., allogeneic) proteins to act as immunogens alone or together with HIV/SIV immunogens
  • Previously unexplored HIV-/SIV-encoded targets as immunogens
  • Vaccine induced/imprinted innate immune responses that can be recalled in response to subsequent vaccination or infection
  • Functional genomics approaches to dissect effective adaptive and/or innate mucosal/systemic immune responses to vaccines

Pilot Clinical Trials Targeting HIV Reservoirs in Children

For the published request for applications, see the December 5, 2016 Guide​ announcement​, Pilot Clinical T​rials Targeting HIV-1 Reservoirs in Children (U01​)​​​.

Simulation Science for HIV: Optimizing New Intervention Strategies Prior to Clinical Trials

Request for Applications—proposed FY 2018 initiative

Contact: David Burns

Objective:

  1. Develop and validate synthetic databases that can be used to examine HIV transmission dynamics and estimate the impact of HIV treatment and prevention interventions
  2. Develop a platform that permits other qualified researchers to use these databases

Description:

  1. The development and validation of a synthetic database that can be used to examine HIV transmission dynamics and estimate the impact of HIV prevention interventions.
  2. An online platform that can be used for these purposes by other qualified researchers.

Appropriately constructed and validated synthetic databases offer a valuable methodology to examine HIV transmission dynamics and estimate the impact of HIV treatment and prevention interventions. Given that HIV prevention trials with active comparator arms require large sample sizes and major funding, use of computational models and simulation analysis to formulate and target particular prevention interventions and combination strategies for implementation could result in considerable cost savings. This approach should also be helpful to optimize the design of prevention interventions that go to randomized clinical trials.  

The initiative will use a phased award mechanism. Phase 1 will support milestone-driven development and validation of a synthetic database that can be used to examine HIV transmission dynamics and estimate the impact of HIV prevention interventions.  Phase 2 will support development of an accessible platform that can be used by other researchers.

Key features for projects include:

  • Acquire access data that can be used to construct synthetic populations with key parameters that determine HIV transmission and acquisition
  • Modular, object-oriented software design to allow rapid adaption to a variety of scenarios
  • Scalable and efficient simulation methodologies that can be run on a variety of computer platforms 
  • Flexible ways to examine various prevention modalities and combination strategies

This funding opportunity announcement will not support:

  • Phase IIb, III, or IV clinical trials
  • Establishment of cohorts
  • Clinical trial planning activities

Tracking HIV Networks Through Phylodynamics

For the published program announcement with special receipt, referral, and/or review considerations, see the November 4, 2016 Guide announcement, Phylodynamic Tracking of HIV Transmission (R01).

Centers for AIDS Research

For the published program announcement, see the March 30, 2017 Guide announcement, Centers for AIDS Research.

Developmental Centers for AIDS Research

For the published program announcement, see the March 30, 2017 Guide announcement, Developmental Centers for AIDS Research.

NK Cells to Induce Immunological Memory to Prevent HIV Infection

For the published program announcement, see the January 9, 2017 Guide announcement, NK Cells to Induce Immunological Memory to Prevent HIV Infection (R01)

Fc Receptor and Antibody Effector Function in HIV Vaccine Discovery

For the published program announcement, see the January 9, 2017 Guide announcement, Fc Receptor and Antibody Effector Function in HIV Vaccine Discovery.

Content last reviewed on March 31, 2017